ATE433972T1 - Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungen - Google Patents
Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungenInfo
- Publication number
- ATE433972T1 ATE433972T1 AT05773671T AT05773671T ATE433972T1 AT E433972 T1 ATE433972 T1 AT E433972T1 AT 05773671 T AT05773671 T AT 05773671T AT 05773671 T AT05773671 T AT 05773671T AT E433972 T1 ATE433972 T1 AT E433972T1
- Authority
- AT
- Austria
- Prior art keywords
- obesity
- treatment
- concentrating hormone
- related diseases
- hormone receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 title 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 3
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 3
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58849204P | 2004-07-16 | 2004-07-16 | |
| PCT/US2005/025060 WO2006019957A2 (en) | 2004-07-16 | 2005-07-14 | Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE433972T1 true ATE433972T1 (de) | 2009-07-15 |
Family
ID=35615552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05773671T ATE433972T1 (de) | 2004-07-16 | 2005-07-14 | Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7361769B2 (de) |
| EP (1) | EP1773822B1 (de) |
| JP (1) | JP2008506705A (de) |
| CN (1) | CN101014589A (de) |
| AT (1) | ATE433972T1 (de) |
| CA (1) | CA2573772A1 (de) |
| DE (1) | DE602005014985D1 (de) |
| ES (1) | ES2327763T3 (de) |
| MX (1) | MX2007000621A (de) |
| WO (1) | WO2006019957A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05208948A (ja) * | 1991-04-04 | 1993-08-20 | Yoshitomi Pharmaceut Ind Ltd | シクロアルキルウレア化合物 |
| US20010049373A1 (en) * | 2000-01-28 | 2001-12-06 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
| US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
| AR037429A1 (es) * | 2001-11-26 | 2004-11-10 | Schering Corp | Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc |
| ES2312637T3 (es) * | 2001-12-04 | 2009-03-01 | Schering Corporation | Derivados de n-aril-n`-arilcicloalquil-urea como antagonistas de mch para el tratamiento de la obesidad. |
| ES2326980T3 (es) * | 2003-10-02 | 2009-10-22 | Schering Corporation | Aminobenzimidazoles utiles como antagonistas selectivos del receptor de la hormona concentrada de melamina (mch) para el tratamiento de la obesidad y desordenes asociados. |
-
2005
- 2005-07-14 AT AT05773671T patent/ATE433972T1/de not_active IP Right Cessation
- 2005-07-14 US US11/181,255 patent/US7361769B2/en not_active Expired - Fee Related
- 2005-07-14 DE DE602005014985T patent/DE602005014985D1/de not_active Expired - Lifetime
- 2005-07-14 WO PCT/US2005/025060 patent/WO2006019957A2/en not_active Ceased
- 2005-07-14 CA CA002573772A patent/CA2573772A1/en not_active Abandoned
- 2005-07-14 MX MX2007000621A patent/MX2007000621A/es active IP Right Grant
- 2005-07-14 EP EP05773671A patent/EP1773822B1/de not_active Expired - Lifetime
- 2005-07-14 ES ES05773671T patent/ES2327763T3/es not_active Expired - Lifetime
- 2005-07-14 CN CNA200580030033XA patent/CN101014589A/zh active Pending
- 2005-07-14 JP JP2007521651A patent/JP2008506705A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2573772A1 (en) | 2006-02-23 |
| WO2006019957A2 (en) | 2006-02-23 |
| EP1773822B1 (de) | 2009-06-17 |
| HK1100176A1 (en) | 2007-09-07 |
| DE602005014985D1 (de) | 2009-07-30 |
| US7361769B2 (en) | 2008-04-22 |
| EP1773822A2 (de) | 2007-04-18 |
| ES2327763T3 (es) | 2009-11-03 |
| JP2008506705A (ja) | 2008-03-06 |
| US20060106031A1 (en) | 2006-05-18 |
| MX2007000621A (es) | 2007-03-07 |
| WO2006019957A3 (en) | 2006-04-27 |
| CN101014589A (zh) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050749L (no) | Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| BR0208150A (pt) | Antagonistas de mch e sua aplicação no tratamento da obesidade | |
| EA200300944A1 (ru) | Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина | |
| DE60232238D1 (de) | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten | |
| EP1610789A4 (de) | Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten | |
| ATE411021T1 (de) | Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| EP1372653A4 (de) | Acylierte piperidin-derivative als melanocortin-4-rezeptor-agonisten | |
| EA200101019A1 (ru) | Модуляторы рецепторов глюкокортикоидов | |
| ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
| MX2007004306A (es) | Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados. | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| DE60307289D1 (de) | Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit | |
| MXPA05009193A (es) | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. | |
| MX2007011848A (es) | Antagonistas del receptor de procineticina i. | |
| DE602005004547D1 (de) | Pyrimdobenzimidazolderivate und verwendung damit als agonisten oder antagonisten von melanocortinrezeptoren | |
| ATE432702T1 (de) | Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen | |
| EP1773338A4 (de) | Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten | |
| ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
| DE602005014985D1 (de) | Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungen | |
| ATE456953T1 (de) | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga | |
| ATE512959T1 (de) | 2-substituierte benzimidazolpiperidinanaloga als selektive antagonisten des auf das melanin- konzentrierende hormon wirkenden rezeptors zur behandlung von obesitas und verwandten erkrankungen | |
| DE60321354D1 (de) | Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen | |
| ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |